Stockscreener 앱 받기
3.92
1.75%
-0.07
시간 외 거래:
3.87
-0.05
-1.28%
전일 마감가:
$3.99
열려 있는:
$3.98
하루 거래량:
90,535
Relative Volume:
0.66
시가총액:
$16.66M
수익:
-
순이익/손실:
$-21.21M
주가수익비율:
-0.1202
EPS:
-32.6
순현금흐름:
$-16.86M
1주 성능:
+7.10%
1개월 성능:
-6.22%
6개월 성능:
-10.09%
1년 성능:
-54.45%
1일 변동 폭
$3.86
$4.04
1주일 범위
$3.5407
$4.0845
52주 변동 폭
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
명칭
Cingulate Inc
전화
(913) 942-2300
주소
1901 W. 47TH PLACE, KANSAS CITY
CING을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.92 | 15.54M | 0 | -21.21M | -16.86M | -32.60 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2023-12-22 | 다운그레이드 | Laidlaw | Buy → Hold |
Cingulate Inc 주식(CING)의 최신 뉴스
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING Stock News - GuruFocus
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Trea - GuruFocus
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus
Cingulate receives FDA meeting feedback on ADHD drug - Investing.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - GlobeNewswire
Cingulate Inc. Receives Formal Pre-New Drug Application Meeting Minutes from the U.S. Food and Drug Administration - marketscreener.com
Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks
Cingulate Inc. Reports First Quarter 2025 Financial Results - GlobeNewswire
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - Stock Titan
27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks
CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus
Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks
Cingulate Announces Positive Top-Line Results from - GlobeNewswire
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - The Manila Times
Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World
Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail
Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance
Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals
CING: 2024 Financial and Operational Results - Yahoo Finance
Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks
Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire
Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan
Cingulate moves closer to ADHD drug submission By Investing.com - Investing.com South Africa
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - GlobeNewswire
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating - TipRanks
Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301 - MarketScreener
Cingulate moves closer to ADHD drug submission - Investing.com
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301 - TipRanks
Breakthrough ADHD Treatment Clears Critical FDA Hurdle: Once-Daily Drug Shows Promise - Stock Titan
Cingulate Inc (CING) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):